Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 306

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Status: Active
Location: See ClinicalTrials.gov
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Location: See ClinicalTrials.gov
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Status: Active
Location: See ClinicalTrials.gov
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
Acetylcysteine for the Mitigation of Chemotherapy-Related Cognitive Impairment in Ovarian Cancer Patients Receiving Platinum-Based Therapy
Status: Approved
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas